101
|
Wang X, Li X, Ito A, Watanabe Y, Sogo Y, Hirose M, Ohno T, Tsuji NM. Rod-shaped and substituted hydroxyapatite nanoparticles stimulating type 1 and 2 cytokine secretion. Colloids Surf B Biointerfaces 2016; 139:10-6. [DOI: 10.1016/j.colsurfb.2015.12.004] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2015] [Revised: 11/29/2015] [Accepted: 12/01/2015] [Indexed: 01/28/2023]
|
102
|
Kamaly N, Yameen B, Wu J, Farokhzad OC. Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release. Chem Rev 2016; 116:2602-63. [PMID: 26854975 PMCID: PMC5509216 DOI: 10.1021/acs.chemrev.5b00346] [Citation(s) in RCA: 1555] [Impact Index Per Article: 194.4] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Affiliation(s)
- Nazila Kamaly
- Laboratory of Nanomedicine and Biomaterials, Department of Anesthesiology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts 02115, United States
| | - Basit Yameen
- Laboratory of Nanomedicine and Biomaterials, Department of Anesthesiology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts 02115, United States
| | - Jun Wu
- Laboratory of Nanomedicine and Biomaterials, Department of Anesthesiology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts 02115, United States
| | - Omid C. Farokhzad
- Laboratory of Nanomedicine and Biomaterials, Department of Anesthesiology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts 02115, United States
- King Abdulaziz University, Jeddah 21589, Saudi Arabia
| |
Collapse
|
103
|
Kokate RA, Chaudhary P, Sun X, Thamake SI, Maji S, Chib R, Vishwanatha JK, Jones HP. Rationalizing the use of functionalized poly-lactic-co-glycolic acid nanoparticles for dendritic cell-based targeted anticancer therapy. Nanomedicine (Lond) 2016; 11:479-94. [PMID: 26892440 DOI: 10.2217/nnm.15.213] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
BACKGROUND Delivery of PLGA (poly [D, L-lactide-co-glycolide])-based biodegradable nanoparticles (NPs) to antigen presenting cells, particularly dendritic cells, has potential for cancer immunotherapy. MATERIALS & METHODS Using a PLGA NP vaccine construct CpG-NP-Tag (CpG-ODN-coated tumor antigen [Tag] encapsulating NP) prepared using solvent evaporation technique we tested the efficacy of ex vivo and in vivo use of this construct as a feasible platform for immune-based therapy. RESULTS CpG-NP-Tag NPs were avidly endocytosed and localized in the endosomal compartment of bone marrow-derived dendritic cells. Bone marrow-derived dendritic cells exposed to CpG-NP-Tag NPs exhibited an increased maturation (higher CD80/86 expression) and activation status (enhanced IL-12 secretion levels). In vivo results demonstrated attenuation of tumor growth and angiogenesis as well as induction of potent cytotoxic T-lymphocyte responses. CONCLUSION Collectively, results validate dendritic cells stimulatory response to CpG-NP-Tag NPs (ex vivo) and CpG-NP-Tag NPs' tumor inhibitory potential (in vivo) for therapeutic applications, respectively.
Collapse
Affiliation(s)
- Rutika A Kokate
- Department of Molecular & Medical Genetics, University of North Texas Health Science Center (UNTHSC), 3500 Camp Bowie Boulevard, Fort Worth, TX 76107, USA.,Institute of Cancer Research, University of North Texas Health Science Center (UNTHSC), Fort Worth, TX 76107, USA
| | - Pankaj Chaudhary
- Department of Molecular & Medical Genetics, University of North Texas Health Science Center (UNTHSC), 3500 Camp Bowie Boulevard, Fort Worth, TX 76107, USA.,Institute of Cancer Research, University of North Texas Health Science Center (UNTHSC), Fort Worth, TX 76107, USA
| | - Xiangle Sun
- Department of Cell Biology & Immunology, University of North Texas Health Science Center (UNTHSC), Fort Worth, TX 76107, USA
| | - Sanjay I Thamake
- Department of Molecular & Medical Genetics, University of North Texas Health Science Center (UNTHSC), 3500 Camp Bowie Boulevard, Fort Worth, TX 76107, USA.,Institute of Cancer Research, University of North Texas Health Science Center (UNTHSC), Fort Worth, TX 76107, USA.,RadioMedix Inc., 9701 Richmond Avenue, Suite 222, Houston, TX 77042, USA
| | - Sayantan Maji
- Department of Molecular & Medical Genetics, University of North Texas Health Science Center (UNTHSC), 3500 Camp Bowie Boulevard, Fort Worth, TX 76107, USA.,Institute of Cancer Research, University of North Texas Health Science Center (UNTHSC), Fort Worth, TX 76107, USA
| | - Rahul Chib
- Department of Cell Biology & Immunology, University of North Texas Health Science Center (UNTHSC), Fort Worth, TX 76107, USA
| | - Jamboor K Vishwanatha
- Department of Molecular & Medical Genetics, University of North Texas Health Science Center (UNTHSC), 3500 Camp Bowie Boulevard, Fort Worth, TX 76107, USA.,Institute of Cancer Research, University of North Texas Health Science Center (UNTHSC), Fort Worth, TX 76107, USA
| | - Harlan P Jones
- Department of Molecular & Medical Genetics, University of North Texas Health Science Center (UNTHSC), 3500 Camp Bowie Boulevard, Fort Worth, TX 76107, USA.,Institute of Cancer Research, University of North Texas Health Science Center (UNTHSC), Fort Worth, TX 76107, USA
| |
Collapse
|
104
|
Gunay MS, Ozer AY, Chalon S. Drug Delivery Systems for Imaging and Therapy of Parkinson's Disease. Curr Neuropharmacol 2016; 14:376-91. [PMID: 26714584 PMCID: PMC4876593 DOI: 10.2174/1570159x14666151230124904] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2015] [Revised: 12/03/2015] [Accepted: 12/29/2015] [Indexed: 12/12/2022] Open
Abstract
BACKGROUND Although a variety of therapeutic approaches are available for the treatment of Parkinson's disease, challenges limit effective therapy. Among these challenges are delivery of drugs through the blood brain barier to the target brain tissue and the side effects observed during long term administration of antiparkinsonian drugs. The use of drug delivery systems such as liposomes, niosomes, micelles, nanoparticles, nanocapsules, gold nanoparticles, microspheres, microcapsules, nanobubbles, microbubbles and dendrimers is being investigated for diagnosis and therapy. METHODS This review focuses on formulation, development and advantages of nanosized drug delivery systems which can penetrate the central nervous system for the therapy and/or diagnosis of PD, and highlights future nanotechnological approaches. RESULTS It is esential to deliver a sufficient amount of either therapeutic or radiocontrast agents to the brain in order to provide the best possible efficacy or imaging without undesired degradation of the agent. Current treatments focus on motor symptoms, but these treatments generally do not deal with modifying the course of Parkinson's disease. Beyond pharmacological therapy, the identification of abnormal proteins such as α -synuclein, parkin or leucine-rich repeat serine/threonine protein kinase 2 could represent promising alternative targets for molecular imaging and therapy of Parkinson's disease. CONCLUSION Nanotechnology and nanosized drug delivery systems are being investigated intensely and could have potential effect for Parkinson's disease. The improvement of drug delivery systems could dramatically enhance the effectiveness of Parkinson's Disease therapy and reduce its side effects.
Collapse
Affiliation(s)
| | - A Yekta Ozer
- Department of Radiopharmacy, Faculty of Pharmacy, Hacettepe University, 06100, Sihhiye, Ankara, Turkey.
| | | |
Collapse
|
105
|
Yang H. Targeted nanosystems: Advances in targeted dendrimers for cancer therapy. NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE 2015; 12:309-16. [PMID: 26706410 DOI: 10.1016/j.nano.2015.11.012] [Citation(s) in RCA: 55] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/30/2015] [Revised: 11/19/2015] [Accepted: 11/24/2015] [Indexed: 12/18/2022]
Abstract
UNLABELLED Dendrimers possess discrete highly compact nanostructures constituted of successive branched layers. Soon after the inception of dendrimers, recognition of their tunable structures and biologically favorable properties provoked a great enthusiasm in delving deeply into the utility of dendrimers for biomedical and pharmaceutical applications. One of the most important nanotechnology applications is the development of nanomedicines for targeted cancer therapies. Tremendous success in targeted therapies has been achieved with the use of dendrimer-based nanomedicines. This article provides a concise review on latest advances in the utility of dendrimers in immunotherapies and hormone therapies. FROM THE CLINICAL EDITOR Much basic and clinical research has been done since the invention of dendrimers, which are highly branched nano-sized molecules with the ability to act as carriers in nanomedicine. In this concise review article, the authors highlighted the current use of dendrimers in immunotherapies and hormone therapies in the fight against cancers.
Collapse
Affiliation(s)
- Hu Yang
- Department of Chemical and Life Science Engineering, Virginia Commonwealth University, Richmond, VA, USA; Department of Pharmaceutics, Virginia Commonwealth University, Richmond, VA, USA; Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA.
| |
Collapse
|
106
|
Wang X, Li X, Ito A, Watanabe Y, Sogo Y, Tsuji NM, Ohno T. Stimulation of In Vivo Antitumor Immunity with Hollow Mesoporous Silica Nanospheres. Angew Chem Int Ed Engl 2015. [DOI: 10.1002/ange.201506179] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- Xiupeng Wang
- Health Research Institute, Department of Life Science and Biotechnology; National Institute of Advanced Industrial Science and Technology (AIST); Central 6, 1-1-1 Higashi Tsukuba Ibaraki 305-8566 Japan
| | - Xia Li
- Health Research Institute, Department of Life Science and Biotechnology; National Institute of Advanced Industrial Science and Technology (AIST); Central 6, 1-1-1 Higashi Tsukuba Ibaraki 305-8566 Japan
| | - Atsuo Ito
- Health Research Institute, Department of Life Science and Biotechnology; National Institute of Advanced Industrial Science and Technology (AIST); Central 6, 1-1-1 Higashi Tsukuba Ibaraki 305-8566 Japan
| | - Yohei Watanabe
- Biomedical Research Institute, Department of Life Science and Biotechnology; National Institute of Advanced Industrial Science and Technology (AIST); Central 6, 1-1-1 Higashi Tsukuba Ibaraki 305-8566 Japan
| | - Yu Sogo
- Health Research Institute, Department of Life Science and Biotechnology; National Institute of Advanced Industrial Science and Technology (AIST); Central 6, 1-1-1 Higashi Tsukuba Ibaraki 305-8566 Japan
| | - Noriko M. Tsuji
- Biomedical Research Institute, Department of Life Science and Biotechnology; National Institute of Advanced Industrial Science and Technology (AIST); Central 6, 1-1-1 Higashi Tsukuba Ibaraki 305-8566 Japan
| | - Tadao Ohno
- School of Life Dentistry at Tokyo; The Nippon Dental University; Fujimi Chiyoda-ku Tokyo 102-0071 Japan
| |
Collapse
|
107
|
Wang X, Li X, Ito A, Watanabe Y, Sogo Y, Tsuji NM, Ohno T. Stimulation of In Vivo Antitumor Immunity with Hollow Mesoporous Silica Nanospheres. Angew Chem Int Ed Engl 2015; 55:1899-903. [DOI: 10.1002/anie.201506179] [Citation(s) in RCA: 100] [Impact Index Per Article: 11.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2015] [Revised: 08/25/2015] [Indexed: 11/09/2022]
Affiliation(s)
- Xiupeng Wang
- Health Research Institute, Department of Life Science and Biotechnology; National Institute of Advanced Industrial Science and Technology (AIST); Central 6, 1-1-1 Higashi Tsukuba Ibaraki 305-8566 Japan
| | - Xia Li
- Health Research Institute, Department of Life Science and Biotechnology; National Institute of Advanced Industrial Science and Technology (AIST); Central 6, 1-1-1 Higashi Tsukuba Ibaraki 305-8566 Japan
| | - Atsuo Ito
- Health Research Institute, Department of Life Science and Biotechnology; National Institute of Advanced Industrial Science and Technology (AIST); Central 6, 1-1-1 Higashi Tsukuba Ibaraki 305-8566 Japan
| | - Yohei Watanabe
- Biomedical Research Institute, Department of Life Science and Biotechnology; National Institute of Advanced Industrial Science and Technology (AIST); Central 6, 1-1-1 Higashi Tsukuba Ibaraki 305-8566 Japan
| | - Yu Sogo
- Health Research Institute, Department of Life Science and Biotechnology; National Institute of Advanced Industrial Science and Technology (AIST); Central 6, 1-1-1 Higashi Tsukuba Ibaraki 305-8566 Japan
| | - Noriko M. Tsuji
- Biomedical Research Institute, Department of Life Science and Biotechnology; National Institute of Advanced Industrial Science and Technology (AIST); Central 6, 1-1-1 Higashi Tsukuba Ibaraki 305-8566 Japan
| | - Tadao Ohno
- School of Life Dentistry at Tokyo; The Nippon Dental University; Fujimi Chiyoda-ku Tokyo 102-0071 Japan
| |
Collapse
|
108
|
Trovato M, Berardinis PD. Novel antigen delivery systems. World J Virol 2015; 4:156-168. [PMID: 26279977 PMCID: PMC4534807 DOI: 10.5501/wjv.v4.i3.156] [Citation(s) in RCA: 37] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/26/2015] [Revised: 06/23/2015] [Accepted: 08/03/2015] [Indexed: 02/05/2023] Open
Abstract
Vaccines represent the most relevant contribution of immunology to human health. However, despite the remarkable success achieved in the past years, many vaccines are still missing in order to fight important human pathologies and to prevent emerging and re-emerging diseases. For these pathogens the known strategies for making vaccines have been unsuccessful and thus, new avenues should be investigated to overcome the failure of clinical trials and other important issues including safety concerns related to live vaccines or viral vectors, the weak immunogenicity of subunit vaccines and side effects associated with the use of adjuvants. A major hurdle of developing successful and effective vaccines is to design antigen delivery systems in such a way that optimizes antigen presentation and induces broad protective immune responses. Recent advances in vector delivery technologies, immunology, vaccinology and system biology, have led to a deeper understanding of the molecular and cellular mechanisms by which vaccines should stimulate both arms of the adaptive immune responses, offering new strategies of vaccinations. This review is an update of current strategies with respect to live attenuated and inactivated vaccines, DNA vaccines, viral vectors, lipid-based carrier systems such as liposomes and virosomes as well as polymeric nanoparticle vaccines and virus-like particles. In addition, this article will describe our work on a versatile and immunogenic delivery system which we have studied in the past decade and which is derived from a non-pathogenic prokaryotic organism: the “E2 scaffold” of the pyruvate dehydrogenase complex from Geobacillus stearothermophilus.
Collapse
|
109
|
Sainz V, Conniot J, Matos AI, Peres C, Zupancic E, Moura L, Silva LC, Florindo HF, Gaspar RS. Regulatory aspects on nanomedicines. Biochem Biophys Res Commun 2015; 468:504-10. [PMID: 26260323 DOI: 10.1016/j.bbrc.2015.08.023] [Citation(s) in RCA: 168] [Impact Index Per Article: 18.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2015] [Accepted: 08/05/2015] [Indexed: 12/11/2022]
Abstract
Nanomedicines have been in the forefront of pharmaceutical research in the last decades, creating new challenges for research community, industry, and regulators. There is a strong demand for the fast development of scientific and technological tools to address unmet medical needs, thus improving human health care and life quality. Tremendous advances in the biomaterials and nanotechnology fields have prompted their use as promising tools to overcome important drawbacks, mostly associated to the non-specific effects of conventional therapeutic approaches. However, the wide range of application of nanomedicines demands a profound knowledge and characterization of these complex products. Their properties need to be extensively understood to avoid unpredicted effects on patients, such as potential immune reactivity. Research policy and alliances have been bringing together scientists, regulators, industry, and, more frequently in recent years, patient representatives and patient advocacy institutions. In order to successfully enhance the development of new technologies, improved strategies for research-based corporate organizations, more integrated research tools dealing with appropriate translational requirements aiming at clinical development, and proactive regulatory policies are essential in the near future. This review focuses on the most important aspects currently recognized as key factors for the regulation of nanomedicines, discussing the efforts under development by industry and regulatory agencies to promote their translation into the market. Regulatory Science aspects driving a faster and safer development of nanomedicines will be a central issue for the next years.
Collapse
Affiliation(s)
- Vanessa Sainz
- Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Lisbon, Portugal
| | - João Conniot
- Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Lisbon, Portugal
| | - Ana I Matos
- Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Lisbon, Portugal
| | - Carina Peres
- Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Lisbon, Portugal
| | - Eva Zupancic
- Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Lisbon, Portugal
| | - Liane Moura
- Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Lisbon, Portugal
| | - Liana C Silva
- Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Lisbon, Portugal
| | - Helena F Florindo
- Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Lisbon, Portugal
| | - Rogério S Gaspar
- Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Lisbon, Portugal.
| |
Collapse
|
110
|
Fang Z, Wan LY, Chu LY, Zhang YQ, Wu JF. 'Smart' nanoparticles as drug delivery systems for applications in tumor therapy. Expert Opin Drug Deliv 2015; 12:1943-53. [PMID: 26193970 DOI: 10.1517/17425247.2015.1071352] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
INTRODUCTION In the therapy of clinical diseases such as cancer, it is important to deliver drugs directly to tumor sites in order to maximize local drug concentration and reduce side effects. This objective may be realized by using 'smart' nanoparticles (NPs) as drug delivery systems, because they enable dramatic conformational changes in response to specific physical/chemical stimuli from the diseased cells for targeted and controlled drug release. AREAS COVERED In this review, we first briefly summarize the characteristics of 'smart' NPs as drug delivery systems in medical therapy, and then discuss their targeting transport, transmembrane and endosomal escape behaviors. Lastly, we focus on the applications of 'smart' NPs as drug delivery systems for tumor therapy. EXPERT OPINION Biodegradable 'smart' NPs have the potential to achieve maximum efficacy and drug availability at the desired sites, and reduce the harmful side effects for healthy tissues in tumor therapy. It is necessary to select appropriate NPs and modify their characteristics according to treatment strategies of tumor therapy.
Collapse
Affiliation(s)
- Zhi Fang
- a 1 China Three Gorges University, Medical College , Yichang, Hubei 443002, China ;
| | - Lin-Yan Wan
- a 1 China Three Gorges University, Medical College , Yichang, Hubei 443002, China ; .,b 2 China Three Gorges University, Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy , Yichang, Hubei 443002, China
| | - Liang-Yin Chu
- c 3 Sichuan University, School of Chemical Engineering , Chengdu, Sichuan 610065, China.,d 4 Sichuan University, Collaborative Innovation Center for Biomaterials Science and Technology, State Key Laboratory of Polymer Materials Engineering , Chengdu, Sichuan 610065, China
| | - Yan-Qiong Zhang
- a 1 China Three Gorges University, Medical College , Yichang, Hubei 443002, China ;
| | - Jiang-Feng Wu
- a 1 China Three Gorges University, Medical College , Yichang, Hubei 443002, China ; .,b 2 China Three Gorges University, Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy , Yichang, Hubei 443002, China
| |
Collapse
|
111
|
Folate-conjugated nanoparticles as a potent therapeutic approach in targeted cancer therapy. Tumour Biol 2015; 36:5727-42. [PMID: 26142733 DOI: 10.1007/s13277-015-3706-6] [Citation(s) in RCA: 79] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2015] [Accepted: 06/22/2015] [Indexed: 01/01/2023] Open
Abstract
The selective and efficient drug delivery to tumor cells can remarkably improve different cancer therapeutic approaches. There are several nanoparticles (NPs) which can act as a potent drug carrier for cancer therapy. However, the specific drug delivery to cancer cells is an important issue which should be considered before designing new NPs for in vivo application. It has been shown that cancer cells over-express folate receptor (FR) in order to improve their growth. As normal cells express a significantly lower levels of FR compared to tumor cells, it seems that folate molecules can be used as potent targeting moieties in different nanocarrier-based therapeutic approaches. Moreover, there is evidence which implies folate-conjugated NPs can selectively deliver anti-tumor drugs into cancer cells both in vitro and in vivo. In this review, we will discuss about the efficiency of different folate-conjugated NPs in cancer therapy.
Collapse
|
112
|
Arcangeli A, Becchetti A. Novel perspectives in cancer therapy: Targeting ion channels. Drug Resist Updat 2015; 21-22:11-9. [DOI: 10.1016/j.drup.2015.06.002] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2015] [Revised: 06/24/2015] [Accepted: 06/27/2015] [Indexed: 01/04/2023]
|
113
|
Surface modification of microparticles causes differential uptake responses in normal and tumoral human breast epithelial cells. Sci Rep 2015; 5:11371. [PMID: 26068810 PMCID: PMC5155550 DOI: 10.1038/srep11371] [Citation(s) in RCA: 58] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2014] [Accepted: 05/26/2015] [Indexed: 02/07/2023] Open
Abstract
The use of micro- and nanodevices as multifunctional systems for biomedical applications has experienced an exponential growth during the past decades. Although a large number of studies have focused on the design and fabrication of new micro- and nanosystems capable of developing multiple functions, a deeper understanding of their interaction with cells is required. In the present study, we evaluated the effect of different microparticle surfaces on their interaction with normal and tumoral human breast epithelial cell lines. For this, AlexaFluor488 IgG functionalized polystyrene microparticles (3 μm) were coated with Polyethyleneimine (PEI) at two different molecular weights, 25 and 750 kDa. The effect of microparticle surface properties on cytotoxicity, cellular uptake and endocytic pathways were assessed for both normal and tumoral cell lines. Results showed a differential response between the two cell lines regarding uptake efficiency and mechanisms of endocytosis, highlighting the potential role of microparticle surface tunning for specific cell targeting.
Collapse
|
114
|
Zhang Y, Luo W, Wang Y, Chen J, Liu Y, Zhang Y. Enhanced antitumor immunity of nanoliposome-encapsulated heat shock protein 70 peptide complex derived from dendritic tumor fusion cells. Oncol Rep 2015; 33:2695-702. [PMID: 25963968 PMCID: PMC4431453 DOI: 10.3892/or.2015.3934] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2015] [Accepted: 03/05/2015] [Indexed: 12/25/2022] Open
Abstract
Tumor-derived heat shock proteins peptide complex (HSP.PC-Tu) has been regarded as a promising antitumor agent. However, inadequate immunogenicity and low bioavailability limit the clinical uses of this agent. In a previous study, we first produced an improved HSP70.PC-based vaccine purified from dendritic cell (DC)-tumor fusion cells (HSP70.PC-Fc) which had increased immunogenicity due to enhanced antigenic tumor peptides compared to HSP70.PC-Tu. In order to increase the bioavailability of HSP70.PC-Fc, the peptide complex was encapsulated with nanoliposomes (NL-HSP70.PC-Fc) in this study. After encapsulation, the tumor immunogenicity was observed using various assays. It was demonstrated that the NL-HSP70.PC-Fc has acceptable stability. The in vivo antitumor immune response was increased with regard to T-cell activation, CTL response and tumor therapy efficiency compared to that of HSP70.PC-Fc. In addition, it was shown that DC maturation was improved by NL-HSP70.PC-Fc, which added to the antitumor immunity. The results obtained for NL-HSP70.PC-Fc, which improved immunogenicity and increases the bioavailability of HSP70.PC, may represent superior heat shock proteins (HSPs)-based tumor vaccines. Such vaccines deserve further investigation and may provide a preclinical rationale to translate findings into early phase trials for patients with breast tumors.
Collapse
Affiliation(s)
- Yunfei Zhang
- Center of Orthopaedic Surgery, Orthopaedics Oncology Institute of Chinese PLA, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710038, P.R. China
| | - Wen Luo
- Department of Ultrasound, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710032, P.R. China
| | - Yucai Wang
- Center of Orthopaedic Surgery, Orthopaedics Oncology Institute of Chinese PLA, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710038, P.R. China
| | - Jun Chen
- Center of Orthopaedic Surgery, Orthopaedics Oncology Institute of Chinese PLA, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710038, P.R. China
| | - Yunyan Liu
- Center of Orthopaedic Surgery, Orthopaedics Oncology Institute of Chinese PLA, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710038, P.R. China
| | - Yong Zhang
- Center of Orthopaedic Surgery, Orthopaedics Oncology Institute of Chinese PLA, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710038, P.R. China
| |
Collapse
|